BioCentury | Jan 31, 2008
Cover Story

CD200: A Solid Argument

...NYSE:SNY) Uvidem Vaccine comprising autologous dendritic cells loaded with melanoma tumor cell lysates Phase II Norwood Immunology Ltd....
BioCentury | Jul 10, 2006
Clinical News

LHRH agonist: Pilot trial data

Norwood Immunology Ltd. (LSE:NIM), Chelsea Heights, Australia Product: LHRH agonist Business: Hematology Molecular target: GnRH/LHRH receptor Description: Luteinizing hormone-releasing hormone (LHRH) agonist Indication: Treat immunodeficiency in patients undergoing bone marrow transplants Endpoint: Renewed thymic function...
BioCentury | Feb 27, 2006
Clinical News

Leupron leuprolide: Phase II started

...months post-transplant. TAP markets Lupron leuprolide for prostate cancer, endometriosis, fibroids and central precocious puberty. Norwood Immunology Ltd....
BioCentury | Jan 30, 2006
Company News

Norwood Immunology, Bestewil Holding BV deal

...$303,100) in Bestewil and will make monthly investments of up to E700,000 ($848,680) this year. Norwood Immunology Ltd....
BioCentury | Jan 3, 2005
Clinical News

Leuprolide: Submitted IND

...next year. TAP markets Lupron leuprolide for prostate cancer, endometriosis, fibroids and central precocious puberty. Norwood Immunology Ltd....
BioCentury | Jul 5, 2004
Finance

Ebb & Flow

...Shire (LSE:SHP; SHPGY) and was recently appointed non-executive chairman of cancer and infectious disease company Norwood Immunology...
BioCentury | Jun 30, 2004
Company News

Newron names Stahel chairman

...Shire (LSE:SHP; SHPGY) and was recently appointed non-executive chairman of cancer and infectious disease company Norwood Immunology...
BioCentury | Jun 28, 2004
Finance

Ebb & Flow

...to treat erectile dysfunction (ED). AD 237 is partnered with Arakis . Australian cancer company Norwood Immunology...
...cancer study of Lupron Depot , a GnRH analog from TAP, in the second half. Norwood Immunology...
BioCentury | Jun 25, 2004
Financial News

Norwood prices IPO

...underwriter. Norwood Immunology's parent company, Norwood Abbey Ltd. (ASX:NAL, Melbourne, Australia), will own about 83% of Norwood Immunology...
BioCentury | Jun 24, 2004
Financial News

Norwood updates IPO

...to raise AUS$37 million. Norwood Immunology's parent company, Norwood Abbey (ASX:NAL), will own about 83% of Norwood Immunology...
Items per page:
1 - 10 of 15
BioCentury | Jan 31, 2008
Cover Story

CD200: A Solid Argument

...NYSE:SNY) Uvidem Vaccine comprising autologous dendritic cells loaded with melanoma tumor cell lysates Phase II Norwood Immunology Ltd....
BioCentury | Jul 10, 2006
Clinical News

LHRH agonist: Pilot trial data

Norwood Immunology Ltd. (LSE:NIM), Chelsea Heights, Australia Product: LHRH agonist Business: Hematology Molecular target: GnRH/LHRH receptor Description: Luteinizing hormone-releasing hormone (LHRH) agonist Indication: Treat immunodeficiency in patients undergoing bone marrow transplants Endpoint: Renewed thymic function...
BioCentury | Feb 27, 2006
Clinical News

Leupron leuprolide: Phase II started

...months post-transplant. TAP markets Lupron leuprolide for prostate cancer, endometriosis, fibroids and central precocious puberty. Norwood Immunology Ltd....
BioCentury | Jan 30, 2006
Company News

Norwood Immunology, Bestewil Holding BV deal

...$303,100) in Bestewil and will make monthly investments of up to E700,000 ($848,680) this year. Norwood Immunology Ltd....
BioCentury | Jan 3, 2005
Clinical News

Leuprolide: Submitted IND

...next year. TAP markets Lupron leuprolide for prostate cancer, endometriosis, fibroids and central precocious puberty. Norwood Immunology Ltd....
BioCentury | Jul 5, 2004
Finance

Ebb & Flow

...Shire (LSE:SHP; SHPGY) and was recently appointed non-executive chairman of cancer and infectious disease company Norwood Immunology...
BioCentury | Jun 30, 2004
Company News

Newron names Stahel chairman

...Shire (LSE:SHP; SHPGY) and was recently appointed non-executive chairman of cancer and infectious disease company Norwood Immunology...
BioCentury | Jun 28, 2004
Finance

Ebb & Flow

...to treat erectile dysfunction (ED). AD 237 is partnered with Arakis . Australian cancer company Norwood Immunology...
...cancer study of Lupron Depot , a GnRH analog from TAP, in the second half. Norwood Immunology...
BioCentury | Jun 25, 2004
Financial News

Norwood prices IPO

...underwriter. Norwood Immunology's parent company, Norwood Abbey Ltd. (ASX:NAL, Melbourne, Australia), will own about 83% of Norwood Immunology...
BioCentury | Jun 24, 2004
Financial News

Norwood updates IPO

...to raise AUS$37 million. Norwood Immunology's parent company, Norwood Abbey (ASX:NAL), will own about 83% of Norwood Immunology...
Items per page:
1 - 10 of 15